Oral Estradiol Pre-Surgery Hold Window: When to Stop and When to Restart

What the label actually says

The oral estradiol tablet label, in its warnings section, states: "If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization." [1]

Two parts of that sentence matter as much as the number. The label qualifies the instruction with "if feasible" but does not define when stopping treatment is feasible [1]. And the label names no procedures. Its qualifier is "surgery of the type associated with an increased risk of thromboembolism," plus periods of prolonged immobilization [1].

The Climara estradiol patch label carries a matching instruction: if feasible, discontinue estrogens at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization [2].

What the label clot figures are based on

The clot rates cited in the labels come from trials of oral conjugated estrogens, not estradiol. The Climara label says their relevance to other routes and products is unknown; the oral tablet label says that, without comparable data, the risks of other dosage forms should be assumed to be similar [1][2].

In the estrogen-plus-progestin substudy, VTE occurred at 34 per 10,000 women-years on conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg versus 16 per 10,000 women-years on placebo [1]. In the estrogen-alone substudy, the rate was 30 versus 22 per 10,000 women-years, and only the deep vein thrombosis difference reached statistical significance (23 versus 15 per 10,000 women-years) [2].

The Climara label adds that only daily oral conjugated estrogens 0.625 mg were studied, so the relevance of those findings to lower doses, other routes of administration or other estrogen-alone products is not known [2].

Does the route change the instruction?

The Climara label notes that systemic estradiol availability after transdermal use is about 20 times higher than after oral use because there is no first-pass metabolism [2].

Observational studies reported different clot-risk estimates for oral and transdermal estrogen, but they were not randomized and do not settle why the estimates differed [3][4][5]. In the French ESTHER case-control study, 271 women with a first idiopathic VTE were compared with 610 matched controls: the adjusted odds ratio for VTE was 4.2 (95% CI 1.5 to 11.6) in current oral estrogen users and 0.9 (0.4 to 2.1) in transdermal users [3]. A BMJ meta-analysis of eight observational studies and nine randomized trials reported pooled observational odds ratios of 2.5 (1.9 to 3.4) for oral estrogen and 1.2 (0.9 to 1.7) for transdermal, with oral risk highest in the first year of use (4.0, 2.9 to 5.7) [4]. A UK nested case-control study of 80,396 women with VTE and 391,494 matched controls found an adjusted odds ratio of 1.58 (1.52 to 1.64) for oral therapy and 0.93 (0.87 to 1.01) for transdermal [5].

The patch label still carries the 4-to-6-week instruction [2].

Risk factors the labels flag

Active DVT or PE, or a history of either, is a contraindication to oral estradiol [1] and to the Climara patch [2]. The oral estradiol label lists active or recent arterial thromboembolic disease, such as stroke or myocardial infarction, as a contraindication. Climara lists active arterial thromboembolic disease or a history of it as a contraindication [1][2]. The Climara label also lists protein C, protein S or antithrombin deficiency, or other known thrombophilic disorders [2].

The oral tablet label says VTE risk factors (personal or family history of VTE, obesity, systemic lupus erythematosus) and arterial risk factors (hypertension, diabetes, tobacco use, high cholesterol, obesity) should be managed appropriately [1].

What the trials show about existing clot risk

The clearest randomized evidence on prior VTE comes from EVTET, which assigned 140 women with a previously verified VTE to 2 mg estradiol plus 1 mg norethisterone acetate daily or placebo. Eight women on the hormone arm developed VTE versus one on placebo, 10.7% versus 2.3%, and the trial was stopped early; the investigators concluded that this treatment should be avoided in women with prior VTE if possible [6]. The product tested was an estradiol-norethisterone combination, not estradiol alone [6].

Surgery also appears in the HERS trial, which randomized 2,763 postmenopausal women with coronary heart disease and no prior VTE to conjugated estrogens 0.625 mg plus medroxyprogesterone 2.5 mg or placebo. Among women in that trial, VTE risk was increased for 90 days after inpatient surgery (relative hazard 4.9, 95% CI 2.4 to 9.8) and after nonsurgical hospitalization (5.7, 3.0 to 10.8) [7]. The hormone tested there was also conjugated estrogens, not estradiol [7].

Restart after surgery

The perioperative sentence in the label sits in the warnings section and addresses stopping; it does not state when to restart [1]. The dosing section carries separate routine advice: patients should be reassessed periodically, for example at 3- to 6-month intervals, and attempts to taper or discontinue should be made at 3- to 6-month intervals [1]. The Climara label gives the same 3-to-6-month taper advice [2].

Frequently asked questions